Return to flight with multiple sclerosis: aeromedical considerations

Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aviation, space, and environmental medicine space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64
Hauptverfasser: Zinger, Hasya, Grossman, Alon, Assa, Amit, Barel, Oshri, Barenboim, Erez, Levite, Ronen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 64
container_issue 1
container_start_page 61
container_title Aviation, space, and environmental medicine
container_volume 82
creator Zinger, Hasya
Grossman, Alon
Assa, Amit
Barel, Oshri
Barenboim, Erez
Levite, Ronen
description Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.
doi_str_mv 10.3357/ASEM.2774.2011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_843416303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>843416303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c249t-18901e0a4ebb89ea80d7cbc4a86c396896be83291fa271c9e4a907a11383c5383</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhH0A0VK4ckS5cUpYP5LY3KpSHlIREo-z5bgbauQ0JXaE-PckauGyO4fZ0c5HyAWFjPO8vJ6_Lp8yVpYiY0DpEZkCqDwt8oJNyGkInwDABYMTMmGU8ZyCmpLbF4x9t01im9TefWxi8u3iJml6H93OYxKsx64NLtwkZhANrp01PrHtNrg1dia6QZ2R49r4gOeHPSPvd8u3xUO6er5_XMxXqWVCxZRKBRTBCKwqqdBIWJe2ssLIwnJVSFVUKDlTtDaspFahMApKQymX3ObDmJGrfe6ua796DFE3Llj03myx7YOWggtacOCDM9s77fB86LDWu841pvvRFPQIS4-w9AhLj7CGg8tDdF8NJf_tf6T4L8ctZuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>843416303</pqid></control><display><type>article</type><title>Return to flight with multiple sclerosis: aeromedical considerations</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><creator>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</creator><creatorcontrib>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</creatorcontrib><description>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</description><identifier>ISSN: 0095-6562</identifier><identifier>DOI: 10.3357/ASEM.2774.2011</identifier><identifier>PMID: 21235109</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aerospace Medicine ; Executive Function ; Humans ; Israel ; Male ; Military Personnel ; Multiple Sclerosis - complications ; Multiple Sclerosis - drug therapy ; Neurologic Examination ; Optic Neuritis - drug therapy ; Optic Neuritis - etiology ; Paresthesia - drug therapy ; Paresthesia - etiology ; Space life sciences ; Vision Disorders - drug therapy ; Vision Disorders - etiology ; Work Capacity Evaluation</subject><ispartof>Aviation, space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>214,314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21235109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zinger, Hasya</creatorcontrib><creatorcontrib>Grossman, Alon</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Barel, Oshri</creatorcontrib><creatorcontrib>Barenboim, Erez</creatorcontrib><creatorcontrib>Levite, Ronen</creatorcontrib><title>Return to flight with multiple sclerosis: aeromedical considerations</title><title>Aviation, space, and environmental medicine</title><addtitle>Aviat Space Environ Med</addtitle><description>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</description><subject>Adult</subject><subject>Aerospace Medicine</subject><subject>Executive Function</subject><subject>Humans</subject><subject>Israel</subject><subject>Male</subject><subject>Military Personnel</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Neurologic Examination</subject><subject>Optic Neuritis - drug therapy</subject><subject>Optic Neuritis - etiology</subject><subject>Paresthesia - drug therapy</subject><subject>Paresthesia - etiology</subject><subject>Space life sciences</subject><subject>Vision Disorders - drug therapy</subject><subject>Vision Disorders - etiology</subject><subject>Work Capacity Evaluation</subject><issn>0095-6562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtPwzAQhH0A0VK4ckS5cUpYP5LY3KpSHlIREo-z5bgbauQ0JXaE-PckauGyO4fZ0c5HyAWFjPO8vJ6_Lp8yVpYiY0DpEZkCqDwt8oJNyGkInwDABYMTMmGU8ZyCmpLbF4x9t01im9TefWxi8u3iJml6H93OYxKsx64NLtwkZhANrp01PrHtNrg1dia6QZ2R49r4gOeHPSPvd8u3xUO6er5_XMxXqWVCxZRKBRTBCKwqqdBIWJe2ssLIwnJVSFVUKDlTtDaspFahMApKQymX3ObDmJGrfe6ua796DFE3Llj03myx7YOWggtacOCDM9s77fB86LDWu841pvvRFPQIS4-w9AhLj7CGg8tDdF8NJf_tf6T4L8ctZuA</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Zinger, Hasya</creator><creator>Grossman, Alon</creator><creator>Assa, Amit</creator><creator>Barel, Oshri</creator><creator>Barenboim, Erez</creator><creator>Levite, Ronen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201101</creationdate><title>Return to flight with multiple sclerosis: aeromedical considerations</title><author>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c249t-18901e0a4ebb89ea80d7cbc4a86c396896be83291fa271c9e4a907a11383c5383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aerospace Medicine</topic><topic>Executive Function</topic><topic>Humans</topic><topic>Israel</topic><topic>Male</topic><topic>Military Personnel</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Neurologic Examination</topic><topic>Optic Neuritis - drug therapy</topic><topic>Optic Neuritis - etiology</topic><topic>Paresthesia - drug therapy</topic><topic>Paresthesia - etiology</topic><topic>Space life sciences</topic><topic>Vision Disorders - drug therapy</topic><topic>Vision Disorders - etiology</topic><topic>Work Capacity Evaluation</topic><toplevel>online_resources</toplevel><creatorcontrib>Zinger, Hasya</creatorcontrib><creatorcontrib>Grossman, Alon</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Barel, Oshri</creatorcontrib><creatorcontrib>Barenboim, Erez</creatorcontrib><creatorcontrib>Levite, Ronen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Aviation, space, and environmental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zinger, Hasya</au><au>Grossman, Alon</au><au>Assa, Amit</au><au>Barel, Oshri</au><au>Barenboim, Erez</au><au>Levite, Ronen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Return to flight with multiple sclerosis: aeromedical considerations</atitle><jtitle>Aviation, space, and environmental medicine</jtitle><addtitle>Aviat Space Environ Med</addtitle><date>2011-01</date><risdate>2011</risdate><volume>82</volume><issue>1</issue><spage>61</spage><epage>64</epage><pages>61-64</pages><issn>0095-6562</issn><abstract>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</abstract><cop>United States</cop><pmid>21235109</pmid><doi>10.3357/ASEM.2774.2011</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0095-6562
ispartof Aviation, space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64
issn 0095-6562
language eng
recordid cdi_proquest_miscellaneous_843416303
source MEDLINE; IngentaConnect Free/Open Access Journals
subjects Adult
Aerospace Medicine
Executive Function
Humans
Israel
Male
Military Personnel
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Neurologic Examination
Optic Neuritis - drug therapy
Optic Neuritis - etiology
Paresthesia - drug therapy
Paresthesia - etiology
Space life sciences
Vision Disorders - drug therapy
Vision Disorders - etiology
Work Capacity Evaluation
title Return to flight with multiple sclerosis: aeromedical considerations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A07%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Return%20to%20flight%20with%20multiple%20sclerosis:%20aeromedical%20considerations&rft.jtitle=Aviation,%20space,%20and%20environmental%20medicine&rft.au=Zinger,%20Hasya&rft.date=2011-01&rft.volume=82&rft.issue=1&rft.spage=61&rft.epage=64&rft.pages=61-64&rft.issn=0095-6562&rft_id=info:doi/10.3357/ASEM.2774.2011&rft_dat=%3Cproquest_cross%3E843416303%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=843416303&rft_id=info:pmid/21235109&rfr_iscdi=true